Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer

Summary

Vascarta Inc. presented preclinical and clinical evidence for VAS-101 (Vasceptor), a transdermal curcuminoid therapeutic targeting pain and inflammation across multiple indications including sickle cell disease, osteoarthritis, and cancer as a potential non-opioid alternative.